Astellas Pharma (4503) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026FY 2026 outlook and profitability
Strong Q2 results lifted FY26 revenue guidance by JPY110bn and core operating profit guidance by JPY80bn.
Core operating profit margin target of 30% brought forward from FY27 to FY26.
More than 85% of revenue comes from outside Japan; the U.S. accounts for almost 45%, with products sold in more than 70 countries.
Growth strategy and capital allocation
CSP 2026 targets pipeline-led, self-funded growth toward sustainable growth in the mid-2030s; XTANDI U.S. loss of exclusivity starts next August, followed by Europe and other markets.
Plan to double sales of five strategic brands over the next five years; target 30% core operating profit margin after R&D investment of 20% of revenue.
Next five-year cumulative operating profit forecast of JPY4.3tn versus JPY3.4tn in the prior five years, despite declining revenue; planned allocations include JPY2tn for R&D, JPY850bn for strategic investments and JPY750bn for dividends.
Dividend plan commits to annual increases of JPY2 per share over the next five years; cost optimization targets JPY200bn in annual recurring benefits over the plan period, including JPY40bn in FY26 and JPY45bn in FY27.
Business development will prioritize assets that can benefit from existing expertise, often around clinical proof of concept; JPY850bn is secured for strategic investments, averaging JPY100bn per year for BD opportunities.
Pipeline and franchise development
Target of JPY1tn in revenue from the internal pipeline by the mid-2030s; plan to start 10+ pivotal or Phase III studies over five years, including five this year and next year.
Two additional pivotal ASP2138 studies began in the first half; clinical proof of concept declared for VIR-5500, now ASP6958, and other programs advanced into clinical development.
Pipeline strategy builds franchises across prostate cancer, Claudin 18.2 and ophthalmology, linking biology, modality and disease needs.
Latest events from Astellas Pharma
- Raised FY2026 outlook supports a pivot to pipeline-led growth from FY2029.4503
Investor presentation - Strategic Brand growth lifts FY2026 core operating profit guidance to ¥700bn.4503
Q2 2027 - Sustainability efforts and governance reforms are driving measurable enterprise value and innovation.4503
Sustainable Meeting 2024 - Record revenue and profit growth led by strategic brands, pipeline advances, and global expansion.4503
Q1 2027 - Pipeline-led growth, high-margin brands, and oncology innovation to drive record revenues.4503
Jefferies Global Healthcare Conference 2026 - Record revenue and profit growth driven by Strategic Brands and cost optimization, with strong FY2026 outlook.4503
Q4 2026 - Double-digit revenue and profit growth led to upward guidance, driven by strategic brands.4503
Q3 2026 - Core operating profit surged 54.4% on 10.1% revenue growth and strong brand sales.4503
Q2 2026 - Q1 revenue up 26.2% year-on-year, driven by XTANDI and strategic brands, with strong profit growth.4503
Q1 2025